1802220-02-5 exporter Competitive price 1802220-02-5 low price 1802220-02-5 TPX-0005 CAS NO.1802220-02-5
- FOB Price: USD: /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: T/T,Other
- Available Specifications:
99%(1-5)Gram98%(1-5)Gram
- Product Details
Keywords
- 1802220-02-5 exporter
- Competitive price 1802220-02-5
- low price 1802220-02-5 TPX-0005
Quick Details
- ProName: 1802220-02-5 exporter Competitive pric...
- CasNo: 1802220-02-5
- Molecular Formula: C18H18FN5O2
- Appearance: Powder
- Application: Scientific research
- DeliveryTime: Prompt
- PackAge: As required
- Port: Shanghai
- ProductionCapacity: 1000 Gram/Week
- Purity: 98%
- Storage: keep sealed and keep from direct light
- Transportation: By Sea/Air/FedEx
- LimitNum: 1 Gram
- Moisture Content: N/A
- Impurity: N/A
- Grade: Industrial Grade,Pharma Grade
Superiority
1802220-02-5 exporter Competitive price 1802220-02-5 low price TPX-0005
TPX-0005 is a multi-kinase inhibitor that inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as C-ros oncogene 1 (ROS1; IC50 = 0.07 nM).It inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively). It inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 lung cancer cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with gefitinib, afatinib, PF-299804 , or osimertinib. TPX-0005 (30 mg/kg) reduces tumor growth in PC-9 and H1975 mouse xenograft models and potentiates the effect of osimertinib in these models.
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs including WT ALK, ALK G1202R and ALK L1196M, respectively).
Details
TPX-0005 is a multi-kinase inhibitor that inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as C-ros oncogene 1 (ROS1, IC50 = 0.07 nM). It inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively). It inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 lung cancer cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with gefitinib (Cay-13166), afatinib (Cay-11492), PF-299804 (dacomitinib, Cay-9001879), or osimertinib. TPX-0005 (30 mg/kg) reduces tumor growth in PC-9 and H1975 mouse xenograft models and potentiates the effect of osimertinib in these models. Formal Name: (7S,13R)-11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-1,15-etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one. CAS Number: 1802220-02-5. Molecular Formula: C18H18FN5O2. Formula Weight: 355.4. Purity: >98%. Formulation: A crystalline solid. Solubility: DMF: 1 mg/ml, DMSO: 0.2 mg/ml. lambdamax: 222, 258 nm. SMILES: C[C@@H](NC1=NC2=C3C=NN2C=C1)C4=CC(F)=CC=C4O[C@@H](C)CNC3=O. InChi Code: InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1. InChi Key: FIKPXCOQUIZNHB-WDEREUQCSA-N.